HC Wainwright Predicts Cingulate’s Q2 Earnings (NASDAQ:CING)

Cingulate Inc. (NASDAQ:CING) – Equities research analysts at HC Wainwright issued their Q2 2026 earnings per share (EPS) estimates for shares of Cingulate in a report issued on Tuesday, May 26th. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings per share of ($0.79) for the quarter. HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Cingulate’s current full-year earnings is ($2.38) per share. HC Wainwright also issued estimates for Cingulate’s Q4 2026 earnings at $0.05 EPS, Q1 2027 earnings at $0.16 EPS, Q2 2027 earnings at $0.40 EPS, Q3 2027 earnings at $0.46 EPS, Q4 2027 earnings at $0.74 EPS and FY2027 earnings at $1.81 EPS.

Cingulate (NASDAQ:CING) last released its earnings results on Thursday, May 14th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.42).

A number of other research analysts have also recently commented on the company. Wall Street Zen cut Cingulate from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Roth Mkm restated a “buy” rating and issued a $10.00 target price on shares of Cingulate in a research note on Tuesday, May 19th. Ascendiant Capital Markets lowered their price objective on Cingulate from $58.00 to $55.00 and set a “buy” rating for the company in a research note on Wednesday, April 8th. Finally, Weiss Ratings upgraded Cingulate from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Cingulate has an average rating of “Moderate Buy” and an average price target of $28.33.

Cingulate Stock Down 17.2%

CING opened at $3.96 on Thursday. The stock has a market cap of $53.34 million, a PE ratio of -0.94 and a beta of -0.81. The business has a 50 day moving average of $5.66 and a 200-day moving average of $5.34. Cingulate has a 52 week low of $3.20 and a 52 week high of $11.89.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in CING. DRW Securities LLC purchased a new position in Cingulate during the fourth quarter valued at $255,000. Renaissance Technologies LLC purchased a new position in Cingulate during the first quarter valued at $198,000. Kestra Advisory Services LLC raised its stake in Cingulate by 29.8% during the fourth quarter. Kestra Advisory Services LLC now owns 122,000 shares of the company’s stock valued at $529,000 after buying an additional 27,979 shares during the last quarter. XTX Topco Ltd purchased a new position in Cingulate during the fourth quarter valued at $90,000. Finally, Chicago Partners Investment Group LLC purchased a new position in Cingulate during the first quarter valued at $116,000. Hedge funds and other institutional investors own 41.31% of the company’s stock.

About Cingulate

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.